Intrexon Corp (XON) 25.33 $XON Purcell Julie &
Post# of 273257
Posted On: 09/05/2016 3:13:43 AM
Intrexon Corp (XON) 25.33 $XON
Purcell Julie & Lefkowitz LLP Is Investigating Intrexon Corporation for Potential Breaches Of Fiduciary Duty By Its Board of Directors
PR Newswire - Thu Sep 01, 6:21AM CDT
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Intrexon Corporation (NYSE: XON).
XON: 25.33 (+0.04)
These Two Companies Are Working On The Zika Virus Cure
Ryan McQueeney - Zacks Investment Research - Wed Aug 31, 11:57AM CDT
As the Zika virus continues to spread, these two companies are looking to find the cure first.
INO: 9.08 (-0.06), XON: 25.33 (+0.04)
ZIOPHARM to Present at the 2016 Wells Fargo Healthcare Conference
GlobeNewswire - Wed Aug 31, 6:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 2016 Wells Fargo Healthcare Conference on Wednesday, September 7, 2016 at 10:30 a.m. E.T. The conference is being held at the Westin Boston Waterfront.
ZIOP: 4.94 (-0.05), XON: 25.33 (+0.04), WFC: 50.55 (+0.12)
Oragenics Receives Supportive FDA Feedback for Initiating a Phase 2 Study Protocol for Oral Mucositis Treatment
BusinessWire - Tue Aug 30, 7:15AM CDT
Oragenics (NYSE MKT: OGEN.BC), a leader in the development of novel antibiotics against infectious disease and developing effective treatments for oral mucositis (OM) today announced that it has received feedback from the U.S. Food and Drug Administration (FDA) in response to the Company's request for a Type C meeting, concerning Phase 2 study protocols for the Company's OM therapeutic candidate, AG013. As part of the clinical protocol for the study, Oragenics expects to file the Investigational New Drug (IND) update in late 2016 and initiate the study with AG013 in the United States and Europe during early 2017.
XON: 25.33 (+0.04), OGEN: 0.68 (+0.03)
Inovio Stock Up as Second Zika Virus Vaccine Study Begins
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:07AM CDT
Inovio Pharmaceuticals' (INO) shares were up after the company started a second study evaluating its preventive Zika vaccine, GLS-5700, in Puerto Rico.
INO: 9.08 (-0.06), ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), XON: 25.33 (+0.04)
Learn how to target a 20% return on Apple, or get option-trade ideas on Resolute Energy Corporation, Autodesk, Intrexon and Energy Transfer Equity or any stock you choose
PR Newswire - Mon Aug 29, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AAPL, ADSK, ETE, REN, and XON.
REN: 22.03 (+4.33), XON: 25.33 (+0.04), ETE: 17.84 (+0.03), AAPL: 107.73 (+1.00), ADSK: 68.01 (+0.64)
Oragenics Selects New Lantibiotic for Further Development in Clostridium difficile Infections
BusinessWire - Tue Aug 23, 7:15AM CDT
Oragenics (NYSE:MKT - OGEN.BC), a leader in the development of new antibiotics against infectious disease and developing effective treatments for oral mucositis, today announced selection of a second generation lantibiotic, OG716, for treatment of Clostridium difficile and plans to begin Investigational New Drug (IND) enabling studies.
XON: 25.33 (+0.04), OGEN: 0.68 (+0.03)
Covered Call reports for Gilead Sciences, Intrexon, Ralph Lauren, Smith & Wesson and Eros International include trade ideas that offer returns of 20% or more!
PR Newswire - Thu Aug 11, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for EROS, GILD, RL, SWHC, and XON.
GILD: 76.89 (-0.53), XON: 25.33 (+0.04), RL: 103.23 (-0.30), EROS: 16.57 (+0.24), SWHC: 27.69 (-1.89)
Arctic® Fuji apple one step closer to U.S. regulatory approval
PR Newswire - Thu Aug 11, 7:30AM CDT
The U.S. Department of Agriculture's (USDA) Animal and Plant Health Inspection Service (APHIS) has publicly shared the final version of Okanagan Specialty Fruits Inc.'s (OSF) petition seeking regulatory approval for Arctic® Fuji apples, a nonbrowning variety produced through biotechnology.
XON: 25.33 (+0.04)
Intrexon (XON) Reports Wider Loss in Q2, Revenues Increase
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 4:10PM CDT
Intrexon (XON) reported a loss of 42 cents per share in second-quarter 2016, compared to the year-ago figure of 37 cents.
ZIOP: 4.94 (-0.05), ANIP: 59.86 (-1.56), XON: 25.33 (+0.04)
Intrexon Announces Second Quarter and First Half 2016 Financial Results
PR Newswire - Tue Aug 09, 3:05PM CDT
Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced its second quarter and first half financial results for 2016.
ZIOP: 4.94 (-0.05), FCSC: 0.89 (-0.01), XON: 25.33 (+0.04)
ZIOPHARM Reports Second-Quarter 2016 Financial Results and Provides Update on Recent Activities
GlobeNewswire - Tue Aug 09, 3:01PM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the second quarter ended June 30, 2016, and provided an update on the Company's recent activities.
ZIOP: 4.94 (-0.05), XON: 25.33 (+0.04)
The Zacks Analyst Blog Highlights: Intrexon, PharMerica, Surgery Partners, Civitas Solutions and Healthways
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Intrexon, PharMerica, Surgery Partners, Civitas Solutions and Healthways
SGRY: 20.04 (+0.91), PMC: 25.95 (+0.76), CIVI: 18.34 (+0.40), HWAY: 24.96 (+0.10), XON: 25.33 (+0.04)
Fibrocell Announces Proposed Public Offering of Common Stock and Warrants
GlobeNewswire - Mon Aug 08, 3:29PM CDT
Fibrocell Science, Inc. (NASDAQ:FCSC) (Fibrocell) today announced that it intends to offer and sell shares of its common stock and related warrants to purchase shares of its common stock in an underwritten public offering. The shares of common stock and related warrants will be immediately separable and will be issued separately. All of the securities in the offering are to be sold by Fibrocell.
FCSC: 0.89 (-0.01), XON: 25.33 (+0.04)
Healthcare Stocks' Aug 9 Earnings Roster: XON, PMC & More
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 8:09AM CDT
Here, we take a look at five healthcare stocks scheduled to report their quarterly figures on Aug 9.
SGRY: 20.04 (+0.91), PMC: 25.95 (+0.76), CIVI: 18.34 (+0.40), XON: 25.33 (+0.04), HWAY: 24.96 (+0.10)
Intrexon Appoints Dr. Andrew J. Last as Chief Operating Officer
PR Newswire - Mon Aug 08, 7:00AM CDT
Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced the appointment of Andrew J. Last, Ph.D., as Chief Operating Officer effective August 29, 2016, reporting to Intrexon's President, Geno Germano. As Chief Operating Officer, Dr. Last will oversee operations across the Company's multiple technology divisions and operating subsidiaries, driving efficiency and effectiveness in the application of the Company's assets toward its development projects, Exclusive Channel Collaborations and direct market plays.
XON: 25.33 (+0.04)
What's in Store for Intrexon (XON) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 3:09AM CDT
Intrexon (XON), which is set to report second-quarter 2016 results on Aug 9, posted a negative surprise of 10.34% last quarter.
ADHD: 4.77 (+0.03), XON: 25.33 (+0.04), MCRB: 10.13 (-0.02), IONS: 29.46 (-0.58)
FDA Publishes Final Finding of No Significant Impact and Environmental Assessment on Oxitec's Self-limiting Mosquito
PR Newswire Europe - Fri Aug 05, 10:16AM CDT
The US Food and Drug Administration's Center for Veterinary Medicine (FDA-CVM) today published a final finding of no significant impact (FONSI) and final environmental assessment (EA) on Oxitec's self-limiting OX513A Aedes aegypti mosquito for an investigational trial in the Florida Keys. The finding concludes that a field trial of the Company's genetically engineered (GE) OX513A mosquitoes in Key Haven, Florida, will not result in a significant impact on the environment.
XON: 25.33 (+0.04)
MKS Instruments, Emerson Electric, Inovio Pharmaceuticals and Intrexon highlighted as Zacks Bull and Bear of the Day
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 8:30AM CDT
MKS Instruments, Emerson Electric, Inovio Pharmaceuticals and Intrexon highlighted as Zacks Bull and Bear of the Day
INO: 9.08 (-0.06), XON: 25.33 (+0.04), EMR: 52.91 (+0.25), MKSI: 49.60 (+0.35)
Purcell Julie & Lefkowitz LLP Is Investigating Intrexon Corporation for Potential Breaches Of Fiduciary Duty By Its Board of Directors
PR Newswire - Thu Sep 01, 6:21AM CDT
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Intrexon Corporation (NYSE: XON).
XON: 25.33 (+0.04)
These Two Companies Are Working On The Zika Virus Cure
Ryan McQueeney - Zacks Investment Research - Wed Aug 31, 11:57AM CDT
As the Zika virus continues to spread, these two companies are looking to find the cure first.
INO: 9.08 (-0.06), XON: 25.33 (+0.04)
ZIOPHARM to Present at the 2016 Wells Fargo Healthcare Conference
GlobeNewswire - Wed Aug 31, 6:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 2016 Wells Fargo Healthcare Conference on Wednesday, September 7, 2016 at 10:30 a.m. E.T. The conference is being held at the Westin Boston Waterfront.
ZIOP: 4.94 (-0.05), XON: 25.33 (+0.04), WFC: 50.55 (+0.12)
Oragenics Receives Supportive FDA Feedback for Initiating a Phase 2 Study Protocol for Oral Mucositis Treatment
BusinessWire - Tue Aug 30, 7:15AM CDT
Oragenics (NYSE MKT: OGEN.BC), a leader in the development of novel antibiotics against infectious disease and developing effective treatments for oral mucositis (OM) today announced that it has received feedback from the U.S. Food and Drug Administration (FDA) in response to the Company's request for a Type C meeting, concerning Phase 2 study protocols for the Company's OM therapeutic candidate, AG013. As part of the clinical protocol for the study, Oragenics expects to file the Investigational New Drug (IND) update in late 2016 and initiate the study with AG013 in the United States and Europe during early 2017.
XON: 25.33 (+0.04), OGEN: 0.68 (+0.03)
Inovio Stock Up as Second Zika Virus Vaccine Study Begins
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:07AM CDT
Inovio Pharmaceuticals' (INO) shares were up after the company started a second study evaluating its preventive Zika vaccine, GLS-5700, in Puerto Rico.
INO: 9.08 (-0.06), ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), XON: 25.33 (+0.04)
Learn how to target a 20% return on Apple, or get option-trade ideas on Resolute Energy Corporation, Autodesk, Intrexon and Energy Transfer Equity or any stock you choose
PR Newswire - Mon Aug 29, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AAPL, ADSK, ETE, REN, and XON.
REN: 22.03 (+4.33), XON: 25.33 (+0.04), ETE: 17.84 (+0.03), AAPL: 107.73 (+1.00), ADSK: 68.01 (+0.64)
Oragenics Selects New Lantibiotic for Further Development in Clostridium difficile Infections
BusinessWire - Tue Aug 23, 7:15AM CDT
Oragenics (NYSE:MKT - OGEN.BC), a leader in the development of new antibiotics against infectious disease and developing effective treatments for oral mucositis, today announced selection of a second generation lantibiotic, OG716, for treatment of Clostridium difficile and plans to begin Investigational New Drug (IND) enabling studies.
XON: 25.33 (+0.04), OGEN: 0.68 (+0.03)
Covered Call reports for Gilead Sciences, Intrexon, Ralph Lauren, Smith & Wesson and Eros International include trade ideas that offer returns of 20% or more!
PR Newswire - Thu Aug 11, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for EROS, GILD, RL, SWHC, and XON.
GILD: 76.89 (-0.53), XON: 25.33 (+0.04), RL: 103.23 (-0.30), EROS: 16.57 (+0.24), SWHC: 27.69 (-1.89)
Arctic® Fuji apple one step closer to U.S. regulatory approval
PR Newswire - Thu Aug 11, 7:30AM CDT
The U.S. Department of Agriculture's (USDA) Animal and Plant Health Inspection Service (APHIS) has publicly shared the final version of Okanagan Specialty Fruits Inc.'s (OSF) petition seeking regulatory approval for Arctic® Fuji apples, a nonbrowning variety produced through biotechnology.
XON: 25.33 (+0.04)
Intrexon (XON) Reports Wider Loss in Q2, Revenues Increase
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 4:10PM CDT
Intrexon (XON) reported a loss of 42 cents per share in second-quarter 2016, compared to the year-ago figure of 37 cents.
ZIOP: 4.94 (-0.05), ANIP: 59.86 (-1.56), XON: 25.33 (+0.04)
Intrexon Announces Second Quarter and First Half 2016 Financial Results
PR Newswire - Tue Aug 09, 3:05PM CDT
Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced its second quarter and first half financial results for 2016.
ZIOP: 4.94 (-0.05), FCSC: 0.89 (-0.01), XON: 25.33 (+0.04)
ZIOPHARM Reports Second-Quarter 2016 Financial Results and Provides Update on Recent Activities
GlobeNewswire - Tue Aug 09, 3:01PM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the second quarter ended June 30, 2016, and provided an update on the Company's recent activities.
ZIOP: 4.94 (-0.05), XON: 25.33 (+0.04)
The Zacks Analyst Blog Highlights: Intrexon, PharMerica, Surgery Partners, Civitas Solutions and Healthways
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Intrexon, PharMerica, Surgery Partners, Civitas Solutions and Healthways
SGRY: 20.04 (+0.91), PMC: 25.95 (+0.76), CIVI: 18.34 (+0.40), HWAY: 24.96 (+0.10), XON: 25.33 (+0.04)
Fibrocell Announces Proposed Public Offering of Common Stock and Warrants
GlobeNewswire - Mon Aug 08, 3:29PM CDT
Fibrocell Science, Inc. (NASDAQ:FCSC) (Fibrocell) today announced that it intends to offer and sell shares of its common stock and related warrants to purchase shares of its common stock in an underwritten public offering. The shares of common stock and related warrants will be immediately separable and will be issued separately. All of the securities in the offering are to be sold by Fibrocell.
FCSC: 0.89 (-0.01), XON: 25.33 (+0.04)
Healthcare Stocks' Aug 9 Earnings Roster: XON, PMC & More
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 8:09AM CDT
Here, we take a look at five healthcare stocks scheduled to report their quarterly figures on Aug 9.
SGRY: 20.04 (+0.91), PMC: 25.95 (+0.76), CIVI: 18.34 (+0.40), XON: 25.33 (+0.04), HWAY: 24.96 (+0.10)
Intrexon Appoints Dr. Andrew J. Last as Chief Operating Officer
PR Newswire - Mon Aug 08, 7:00AM CDT
Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced the appointment of Andrew J. Last, Ph.D., as Chief Operating Officer effective August 29, 2016, reporting to Intrexon's President, Geno Germano. As Chief Operating Officer, Dr. Last will oversee operations across the Company's multiple technology divisions and operating subsidiaries, driving efficiency and effectiveness in the application of the Company's assets toward its development projects, Exclusive Channel Collaborations and direct market plays.
XON: 25.33 (+0.04)
What's in Store for Intrexon (XON) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 3:09AM CDT
Intrexon (XON), which is set to report second-quarter 2016 results on Aug 9, posted a negative surprise of 10.34% last quarter.
ADHD: 4.77 (+0.03), XON: 25.33 (+0.04), MCRB: 10.13 (-0.02), IONS: 29.46 (-0.58)
FDA Publishes Final Finding of No Significant Impact and Environmental Assessment on Oxitec's Self-limiting Mosquito
PR Newswire Europe - Fri Aug 05, 10:16AM CDT
The US Food and Drug Administration's Center for Veterinary Medicine (FDA-CVM) today published a final finding of no significant impact (FONSI) and final environmental assessment (EA) on Oxitec's self-limiting OX513A Aedes aegypti mosquito for an investigational trial in the Florida Keys. The finding concludes that a field trial of the Company's genetically engineered (GE) OX513A mosquitoes in Key Haven, Florida, will not result in a significant impact on the environment.
XON: 25.33 (+0.04)
MKS Instruments, Emerson Electric, Inovio Pharmaceuticals and Intrexon highlighted as Zacks Bull and Bear of the Day
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 8:30AM CDT
MKS Instruments, Emerson Electric, Inovio Pharmaceuticals and Intrexon highlighted as Zacks Bull and Bear of the Day
INO: 9.08 (-0.06), XON: 25.33 (+0.04), EMR: 52.91 (+0.25), MKSI: 49.60 (+0.35)
(0)
(0)Scroll down for more posts ▼